Generic User Fees Need Small Business Waiver, Firms Say; Congress May Agree
Executive Summary
Small business owners say the GDUFA facility and other fees are too expensive, especially while waiting for ANDAs to be approved, but any small business waiver is unlikely until GDUFA II.
You may also be interested in...
FDA Reports Millions In Unpaid GDUFA Fees
The $20m in generic drug user fee receivables was 12% of the estimated total to be collected in 2018.
US FDA Reports Millions In Unpaid GDUFA Program Fees
The $20m in generic drug user fee receivables was 12% of the estimated total to be collected in 2018.
ANDA Modifications: US FDA Wants More Formal Facility-Initiated Withdrawals
Facilities that cannot coax an ANDA sponsor to amend their application to exclude a center will have to convince a "less comfortable" FDA with a larger record.